Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05033054 · ClinicalTrials.gov registry record
Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4
A clinical trial, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 33
- Enrollment target
NCT05033054 is a clinical trial that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 33 participants.
The verdict
NCT05033054 has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
This is a prospective, observational study to assess the effect of SGLT2 inhibitors on surrogate markers of kidney and cardiovascular health in patients with stage 3b and 4 chronic kidney disease (CKD). This study includes three clinic in person visits and weekly telephone visits for 12 weeks. 1. Recruit 28 patients with CKD stages 3b-4 and follow up for 12 weeks 2. Determine the effect of interventions on the primary outcome variable serum klotho measured by immunoprecipitation-immunoblot
Interventions
- DRUG SGLT2 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2025-02-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05033054
The ClinicalTrials.gov registry entry for NCT05033054 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGLT2 inhibitor is the first listed.
NCT05033054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05033054 about?
NCT05033054 is a clinical study titled "Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4". This is a prospective, observational study to assess the effect of SGLT2 inhibitors on surrogate markers of kidney and cardiovascular health in patients with stage 3b and 4 chronic kidney disease (CKD). This study includes three clinic in person visits and weekly telephone visits for 12 weeks. 1. ...
What is the current status of trial NCT05033054?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2022-01-01. Estimated completion is 2025-02-01.
What interventions are being tested in trial NCT05033054?
The interventions under investigation include: SGLT2 inhibitor (DRUG).
Who is sponsoring clinical trial NCT05033054?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.